ArticleBritish journal of clinical pharmacology2026
Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
MicroRNA-122 (miR-122) is a sensitive biomarker for paracetamol-induced liver injury. This study assessed the diagnostic performance of dynamic chemical labelling (DCL) combined with an immunoassay platform to quantify miR-122 in human serum, as a proof-of-concept for hospital use. This study used serum samples from 19 healthy individuals and 19 patients with paracetamol drug-induced liver injury (DILI) collected in previous studies. miR-122 was labelled with a biotinylated SMART-Base and quantified using a multiplex, bead-based, fluorescence detection system. The median miR-122 concentration was significantly elevated at 233.4 pg/mL (IQR: 74.5-363.4) compared to 15.2 pg/mL (IQR: 9.4-24) in the control group. The Mann-Whitney U test showed significant group differences (p < 0.0001). ROC analysis yielded an area under the curve (AUC) of 0.96, with a 29.7 pg/mL cut-off providing 92.6% sensitivity (95% CI: 76.6%-98.7%) and 89.4% specificity (95% CI: 68.6%-98.1%). miR-122 moderately correlated with ALT (r = 0.56, p = 0.03). DCL with fluorescence detection is a promising clinical tool for miR-122 quantification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.